The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Open accessAbstract
Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 1×
“In ischemia they promote collateral vessel growth (42), while in tumors M1-polarized macrophages are tumoricidal, but M2-polar-ized macrophages promote tumor vascularization by producing proangiogenic factors (43).”
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 2×
“For instance, pancreatic adenocarcinomas have high interstitial fluid pressure due to abundant deposition of hyaluronic acid, which impairs perfusion and drug distribution (98).”
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Self-citationVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Role of PFKFB3-Driven Glycolysis in Vessel Sprouting
De Bock, K., Georgiadou, M., Schoors, S., Kuchnio, A., Wong, B. W., Cantelmo, A. R., Quaegebeur, A., Ghesquière, B., Cauwenberghs, S., Eelen, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.037 · Cited by 1,551
Self-citationVan Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., et al. (2010) · Nature · doi:10.1038/nature09557 · Cited by 1,379
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T. S., Bochenek, M. L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Lüthi, U., et al. (2010) · Nature · doi:10.1038/nature09002 · Cited by 1,271
Glioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., & Tabar, V. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,203
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Fantin, A., Vieira, J. M., Gestri, G., Denti, L., Schwarz, Q., Prykhozhij, S., Peri, F., Wilson, S. W., & Ruhrberg, C. (2010) · Blood · doi:10.1182/blood-2009-12-257832 · Cited by 1,153 · cited 1×
“Key molecular players discussed in this Review and elsewhere (5, 132) are indicated. genic factors (41).”
Real-time imaging reveals the single steps of brain metastasis formation.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W. E. F., Goldbrunner, R., Herms, J., & Winkler, F. (2010) · Nature Medicine · doi:10.1038/nm.2072 · Cited by 1,138
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,085
Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting
Jakobsson, L., Franco, C. A., Bentley, K., Collins, R. T., Ponsioen, B., Aspalter, I. M., Rosewell, I., Busse, M., Thurston, G., Medvinsky, A., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2103 · Cited by 971
Central nervous system pericytes in health and disease
Winkler, E. A., Bell, R. D., & Zlokovic, B. V. (2011) · Nature Neuroscience · doi:10.1038/nn.2946 · Cited by 962
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Differential macrophage programming in the tumor microenvironment
Ruffell, B., Affara, N. I., & Coussens, L. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.12.001 · Cited by 860
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
Tammela, T., Zarkada, G., Wallgard, E., Murtomäki, A., Suchting, S., Wirzenius, M., Waltari, M., Hellström, M., Schomber, T., Peltonen, R., et al. (2008) · Nature · doi:10.1038/nature07083 · Cited by 813
Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 812
Self-citationRapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
Developmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695
Self-citationGrothey, A., Sugrue, M. M., Purdie, D. M., Dong, W., Sargent, D., Hedrick, E., & Kozloff, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3212 · Cited by 688
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685 · cited 10×
“The field has focused on developing VEGF and VEGFR inhibitors (VEGFIs and VEGFRIs, respectively) (1, 79).”
InfluentialFagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0855 · Cited by 593
Butler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
Self-citationDynamics of endothelial cell behavior in sprouting angiogenesis
Eilken, H. M., & Adams, R. H. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.08.010 · Cited by 561
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 534
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
von Minckwitz, G., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Kreienberg, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111065 · Cited by 530
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R. M., Kesari, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016030108 · Cited by 515
Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58832 · Cited by 479
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours
Beck, B., Driessens, G., Goossens, S., Youssef, K. K., Kuchnio, A., Caauwe, A., Sotiropoulou, P. A., Loges, S., Lapouge, G., Candi, A., et al. (2011) · Nature · doi:10.1038/nature10525 · Cited by 467
Self-citationAngiopoietin-1 is essential in mouse vasculature during development and in response to injury
Jeansson, M., Gawlik, A., Anderson, G., Li, C., Kerjaschki, D., Henkelman, M., & Quaggin, S. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46322 · Cited by 457
Lu, J., Ye, X., Fan, F., Xia, L., Bhattacharya, R., Bellister, S., Tozzi, F., Sceusi, E., Zhou, Y., Tachibana, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.021 · Cited by 447
Sternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Herbst, R. S., Sun, Y., Eberhardt, W. E., Germonpré, P., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 415
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 393
Self-citationJones, C. A., London, N. R., Chen, H., Park, K. W., Sauvaget, D., Stockton, R. A., Wythe, J. D., Suh, W., Larrieu-Lahargue, F., Mukouyama, Y.-S., et al. (2008) · Nature Medicine · doi:10.1038/nm1742 · Cited by 392
Herbst, R. S., Ansari, R., Bustin, F., Flynn, P., Hart, L., Otterson, G. A., Vlahovic, G., Soh, C.-H., O'Connor, P., & Hainsworth, J. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60545-x · Cited by 392
Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase
Guarani, V., Deflorian, G., Franco, C. A., Krüger, M., Phng, L.-K., Bentley, K., Toussaint, L., Dequiedt, F., Mostoslavsky, R., Schmidt, M. H. H., et al. (2011) · Nature · doi:10.1038/nature09917 · Cited by 383
Self-citationCoordinating cell behaviour during blood vessel formation
Geudens, I., & Gerhardt, H. (2011) · Development · doi:10.1242/dev.062323 · Cited by 376
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling
Benedito, R., Rocha, S. F., Woeste, M., Zamykal, M., Radtke, F., Casanovas, O., Duarte, A., Pytowski, B., & Adams, R. H. (2012) · Nature · doi:10.1038/nature10908 · Cited by 362
ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway
Larrivée, B., Prahst, C., Gordon, E., del Toro, R., Mathivet, T., Duarte, A., Simons, M., & Eichmann, A. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.02.005 · Cited by 359
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Nrarp Coordinates Endothelial Notch and Wnt Signaling to Control Vessel Density in Angiogenesis
Phng, L.-K., Potente, M., Leslie, J. D., Babbage, J., Nyqvist, D., Lobov, I., Ondr, J. K., Rao, S., Lang, R. A., Thurston, G., et al. (2009) · Developmental Cell · doi:10.1016/j.devcel.2008.12.009 · Cited by 349
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Markers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 332
Self-citationVEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling
Tammela, T., Zarkada, G., Nurmi, H., Jakobsson, L., Heinolainen, K., Tvorogov, D., Zheng, W., Franco, C. A., Murtomäki, A., Aranda, E., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2331 · Cited by 321 · cited 3×
“The passive signaling operates by phosphorylation of the intracellular VEGFR3 domain via matrix-dependent activation of Src kinase (16).”
InfluentialGaengel, K., Niaudet, C., Hagikura, K., Laviña, B., Muhl, L., Hofmann, J. J., Ebarasi, L., Nyström, S., Rymo, S., Chen, L. L., et al. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.08.005 · Cited by 317
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Ring, L., New, T., Zabski, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398399 · Cited by 312
Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications
Kirschmann, D. A., Seftor, E. A., Hardy, K. M., Seftor, R. E. B., & Hendrix, M. J. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3237 · Cited by 291
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis
Takeda, Y., Costa, S., Delamarre, E., Roncal, C., Leite de Oliveira, R., Squadrito, M. L., Finisguerra, V., Deschoemaeker, S., Bruyère, F., Wenes, M., et al. (2011) · Nature · doi:10.1038/nature10507 · Cited by 286
Chronic DLL4 blockade induces vascular neoplasms
Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D. (2010) · Nature · doi:10.1038/nature08751 · Cited by 280
Eph/ephrin molecules—a hub for signaling and endocytosis
Pitulescu, M. E., & Adams, R. H. (2010) · Genes & Development · doi:10.1101/gad.1973910 · Cited by 276
VEGF signaling inside vascular endothelial cells and beyond
Eichmann, A., & Simons, M. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.02.002 · Cited by 262
Spatial regulation of VEGF receptor endocytosis in angiogenesis
Nakayama, M., Nakayama, A., van Lessen, M., Yamamoto, H., Hoffmann, S., Drexler, H. C. A., Itoh, N., Hirose, T., Breier, G., Vestweber, D., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2679 · Cited by 260
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 259
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
Self-citationTargeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma
Snuderl, M., Batista, A., Kirkpatrick, N. D., Ruiz de Almodovar, C., Riedemann, L., Walsh, E. C., Anolik, R., Huang, Y., Martin, J. D., Kamoun, W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.036 · Cited by 251
Self-citationDistinct Cellular Mechanisms of Blood Vessel Fusion in the Zebrafish Embryo
Herwig, L., Blum, Y., Krudewig, A., Ellertsdottir, E., Lenard, A., Belting, H.-G., & Affolter, M. (2011) · Current Biology · doi:10.1016/j.cub.2011.10.016 · Cited by 248
The neurovascular link in health and disease: molecular mechanisms and therapeutic implications
Quaegebeur, A., Lange, C., & Carmeliet, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.013 · Cited by 247
Self-citationPlGF: A Multitasking Cytokine with Disease-Restricted Activity
Dewerchin, M., & Carmeliet, P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011056 · Cited by 244
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2012) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3182547170 · Cited by 244
Angiopoietin signaling in the vasculature
Eklund, L., & Saharinen, P. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.03.011 · Cited by 242
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
VEGF Inhibition, Hypertension, and Renal Toxicity
Hayman, S. R., Leung, N., Grande, J. P., & Garovic, V. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0242-z · Cited by 230
Daly, C., Eichten, A., Castanaro, C., Pasnikowski, E., Adler, A., Lalani, A. S., Papadopoulos, N., Kyle, A. H., Minchinton, A. I., Yancopoulos, G. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2064 · Cited by 230
Local Guidance of Emerging Vessel Sprouts Requires Soluble Flt-1
Chappell, J. C., Taylor, S. M., Ferrara, N., & Bautch, V. L. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.07.011 · Cited by 225
Karlan, B. Y., Oza, A. M., Richardson, G. E., Provencher, D. M., Hansen, V. L., Buck, M., Chambers, S. K., Ghatage, P., Pippitt, C. H., Brown, J. V., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3178 · Cited by 224
DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
Li, J.-L., Sainson, R. C. A., Oon, C. E., Turley, H., Leek, R., Sheldon, H., Bridges, E., Shi, W., Snell, C., Bowden, E. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1704 · Cited by 224
Stalk Cell Phenotype Depends on Integration of Notch and Smad1/5 Signaling Cascades
Moya, I. M., Umans, L., Maas, E., Pereira, P. N. G., Beets, K., Francis, A., Sents, W., Robertson, E. J., Mummery, C. L., Huylebroeck, D., et al. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.01.007 · Cited by 223
Kim, J., Oh, W.-J., Gaiano, N., Yoshida, Y., & Gu, C. (2011) · Genes & Development · doi:10.1101/gad.2042011 · Cited by 219
Schmoll, H.-J., Cunningham, D., Sobrero, A., Karapetis, C. S., Rougier, P., Koski, S. L., Kocakova, I., Bondarenko, I., Bodoky, G., Mainwaring, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5355 · Cited by 213
Robo4 Maintains Vessel Integrity and Inhibits Angiogenesis by Interacting with UNC5B
Koch, A. W., Mathivet, T., Larrivée, B., Tong, R. K., Kowalski, J., Pibouin-Fragner, L., Bouvrée, K., Stawicki, S., Nicholes, K., Rathore, N., et al. (2011) · Developmental Cell · doi:10.1016/j.devcel.2010.12.001 · Cited by 209
Jahangiri, A., De Lay, M., Miller, L. M., Carbonell, W. S., Hu, Y.-L., Lu, K., Tom, M. W., Paquette, J., Tokuyasu, T. A., Tsao, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1281 · Cited by 202
Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
Gerald, D., Chintharlapalli, S., Augustin, H. G., & Benjamin, L. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4697 · Cited by 202
di Tomaso, E., Snuderl, M., Kamoun, W. S., Duda, D. G., Auluck, P. K., Fazlollahi, L., Andronesi, O. C., Frosch, M. P., Wen, P. Y., Plotkin, S. R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2602 · Cited by 199
Ramlau, R., Gorbunova, V., Ciuleanu, T. E., Novello, S., Ozguroglu, M., Goksel, T., Baldotto, C., Bennouna, J., Shepherd, F. A., Le-Guennec, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6932 · Cited by 188
Lambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70231-0 · Cited by 187
Self-citationOrchestral actions of angiopoietin-1 in vascular regeneration
Koh, G. Y. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.10.010 · Cited by 183
Krueger, J., Liu, D., Scholz, K., Zimmer, A., Shi, Y., Klein, C., Siekmann, A., Schulte-Merker, S., Cudmore, M., Ahmed, A., et al. (2011) · Development · doi:10.1242/dev.063933 · Cited by 177
Fantin, A., Vieira, J. M., Plein, A., Denti, L., Fruttiger, M., Pollard, J. W., & Ruhrberg, C. (2013) · Blood · doi:10.1182/blood-2012-05-424713 · Cited by 177
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 176
Bry, M., Kivelä, R., Holopainen, T., Anisimov, A., Tammela, T., Soronen, J., Silvola, J. M. U., Saraste, A., Jeltsch, M., Korpisalo, P., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.957332 · Cited by 170
Self-citationEndothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success
Branco-Price, C., Zhang, N., Schnelle, M., Evans, C., Katschinski, D. M., Liao, D., Ellies, L., & Johnson, R. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.017 · Cited by 168
Koh, Y. J., Kim, H.-Z., Hwang, S.-I., Lee, J. E., Oh, N., Jung, K., Kim, M., Kim, K. E., Kim, H., Lim, N. K., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.001 · Cited by 166
Essential Roles of EphB Receptors and EphrinB Ligands in Endothelial Cell Function and Angiogenesis
Salvucci, O., & Tosato, G. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-386503-8.00002-8 · Cited by 164
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo
Stenzel, D., Franco, C. A., Estrach, S., Mettouchi, A., Sauvaget, D., Rosewell, I. R., Schertel, A., Armer, H. E. J., Domogatskaya, A., Rodin, S., et al. (2011) · EMBO Reports · doi:10.1038/embor.2011.194 · Cited by 160
Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
Bono, F., Smet, F. D., Herbert, C., Bock, K. D., Γεωργιάδου, Μ., Fons, P., Tjwa, M., Alcouffe, C., Ny, A., Bianciotto, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.019 · Cited by 154
Self-citationPathological neoangiogenesis depends on oxidative stress regulation by ATM
Okuno, Y., Nakamura-Ishizu, A., Otsu, K., Suda, T., & Kubota, Y. (2012) · Nature Medicine · doi:10.1038/nm.2846 · Cited by 152
Schmidt, T., Masouleh, B. K., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., Jonckx, B., Keersmaecker, K. D., Kleppe, M., Tjwa, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.007 · Cited by 140
Self-citationHerbert, C., Schieborr, U., Saxena, K., Juraszek, J., Smet, F. D., Alcouffe, C., Bianciotto, M., Saladino, G., Sibrac, D., Kudlinzki, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.018 · Cited by 139
Self-citationTvorogov, D., Anisimov, A., Zheng, W., Leppänen, V., Tammela, T., Laurinavičius, S., Holnthoner, W., Heloterä, H., Holopainen, T., Jeltsch, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.001 · Cited by 135
Hu-Lowe, D. D., Chen, E., Zhang, L., Watson, K. D., Mancuso, P., Lappin, P., Wickman, G., Chen, J. H., Wang, J., Jiang, X., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1451 · Cited by 130
Padera, T. P., Kuo, A. H., Hoshida, T., Liao, S., Shah, J. L., Kozak, K. R., Fukumura, D., & Jain, R. K. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0182 · Cited by 120
Fantin, A., Schwarz, Q., Davidson, K., Normando, E. M., Denti, L., & Ruhrberg, C. (2011) · Development · doi:10.1242/dev.070037 · Cited by 118
S1P1 inhibits sprouting angiogenesis during vascular development
Shoham, A. B., Malkinson, G., Krief, S., Shwartz, Y., Ely, Y., Ferrara, N., Yaniv, K., & Zelzer, E. (2012) · Development · doi:10.1242/dev.078550 · Cited by 116
Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
Mackey, J. R., Kerbel, R. S., Gelmon, K. A., McLeod, D., Chia, S., Rayson, D., Verma, S., Collins, L. L., Paterson, A. H. G., Robidoux, A., et al. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.002 · Cited by 115
Abengózar, M. Á., de Frutos, S., Ferreiro, S., Soriano, J., Pérez‐Martínez, M., Olmeda, D., Marenchino, M., Cañamero, M., Ortega, S., Megías, D., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380006 · Cited by 114
Zhang, J., Fukuhara, S., Sako, K., Takenouchi, T., Kitani, H., Kume, T., Koh, G., & Mochizuki, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.192641 · Cited by 114
Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
Palma, M. D., & Naldini, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0171 · Cited by 112
Lee, H. K., Chauhan, S. K., Kay, E., & Dana, R. (2011) · Blood · doi:10.1182/blood-2010-09-306928 · Cited by 107
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
Claes, A., Wesseling, P., Jeuken, J. W. M., Maass, C., Heerschap, A., & Leenders, W. P. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0552 · Cited by 105
Ephrin-B2 regulates endothelial cell morphology and motility independently of Eph-receptor binding
Bochenek, M. L., Dickinson, S., Astin, J. W., Adams, R. H., & Nobes, C. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.061903 · Cited by 100
Semaphorin 6A regulates angiogenesis by modulating VEGF signaling.
Segarra, M., Ohnuki, H., Maric, D., Salvucci, O., Hou, X., Kumar, A., Li, X., & Tosato, G. (2012) · Blood · doi:10.1182/blood-2012-02-410076 · Cited by 97
Cerebrovascular disorders: molecular insights and therapeutic opportunities
Storkebaum, E., Quaegebeur, A., Vikkula, M., & Carmeliet, P. (2011) · Nature Neuroscience · doi:10.1038/nn.2947 · Cited by 96
Self-citationChung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Kömüves, L. G., Peale, F. V., Jr., & Ferrara, N. (2012) · The Journal of Pathology · doi:10.1002/path.4052 · Cited by 88
Boscolo, E., Mulliken, J. B., & Bischoff, J. E. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.07.040 · Cited by 84
Signaling Required for Blood Vessel Maintenance: Molecular Basis and Pathological Manifestations
Murakami, M. (2011) · International Journal of Vascular Medicine · doi:10.1155/2012/293641 · Cited by 77
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I. M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4053 · Cited by 75
Saltz, L. B., Badarinath, S., Dakhil, S. R., Bienvenu, B. J., Harker, W. G., Birchfield, G., Tokaz, L. K., Barrera, D., Conkling, P., O’Rourke, M. A., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.05.006 · Cited by 72
McGuire, P. G., Rangasamy, S., Maestas, J., & Das, A. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.235408 · Cited by 65
The yin, the yang, and the Angiopoietin-1
Saharinen, P., & Alitalo, K. K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58196 · Cited by 62
London, N. R., & Li, D. Y. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328345a4b9 · Cited by 51
Stage II and Stage III Colon Cancer: Treatment Advances and Future Directions
Rousseau, B., Chibaudel, B., Bachet, J., Larsen, A. K., Tournigand, C., Louvet, C., André, T., & de Gramont, A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181ddc5bf · Cited by 43
Herbert, S. P., Cheung, J., & Stainier, D. Y. R. (2012) · Current Biology · doi:10.1016/j.cub.2012.07.037 · Cited by 40
Testori, J., Schweighofer, B., Helfrich, I., Sturtzel, C., Lipnik, K., Gesierich, S., Nasarre, P., Hofer-Warbinek, R., Bilban, M., Augustin, H. G., et al. (2011) · Blood · doi:10.1182/blood-2010-07-293209 · Cited by 34
Oubaha, M., Lin, M. I., Margaron, Y., Filion, D., Price, E., Zon, L. I., Côté, J., & Gratton, J. (2012) · Blood · doi:10.1182/blood-2012-03-419721 · Cited by 33
Kindler, H. L., & Bylow, K. A. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0018-z · Cited by 32
Cited by
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Fatty acid carbon is essential for dNTP synthesis in endothelial cells
Schoors, S., Bruning, U., Missiaen, R., Queiroz, K. C. S., Borgers, G., Elia, I., Zecchin, A., Cantelmo, A. R., Christen, S., Goveia, J., et al. (2015) · Nature · doi:10.1038/nature14362 · Cited by 646
Self-citationDefining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Endothelial Cell Metabolism in Normal and Diseased Vasculature
Eelen, G., de Zeeuw, P., Simons, M., & Carmeliet, P. (2015) · Circulation Research · doi:10.1161/circresaha.116.302855 · Cited by 627
Self-citationTherapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Metadata
- Authors
- Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-08-01
- Volume
- 123
- Issue
- 8
- Pages
- 3190-3200
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2003112634
- Cited by
- 591
- References
- 159
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.